Abstract:Highlights • Synergistic Immune Activation: The sustained release of CDDP and DAC triggers Gasdermin E (GSDME)-mediated pyroptosis, which activates the adaptive immune response, while Mn 2+ enhances the activation of innate immunity through the STING pathway. • Significant Anti-Tumor Effects: The immunogel has shown encouraging anti-tumor effects, with an 80 % total survival rate for recurrent tumors and a 60 % survival rate for metastatic tumors. • Simplicity in Formulation and Preparation: The formulation of the immunogel is simple, and the preparation method is easy to handle, offering a promising strategy for postoperative cancer therapy. Tumor recurrence and metastasis after surgery are important factors affecting patient survival. The immunosuppressed tumor microenvironment after surgery reduces the ability of the immune system to clear residual tumor cells, thus increasing the risk of recurrence and metastasis. Currently, immunotherapy-based adjuvant therapy can effectively inhibit tumor recurrence and metastasis after surgery, but simultaneous and efficient synergistic activation of adaptive and innate immunity is a challenge. Here, we utilized polymeric hydrogel loaded with decitabine (DAC), cisplatin (CDDP) and manganese ions (Mn 2+ ) as a postoperative filler immunogel to synergistically activate both anti-tumor innate and adaptive immunity. The sustained release of CDDP and DAC burst gasdermin E (GSDME)-mediated pyroptosis and activated adaptive immunity, while Mn 2+ enhanced intrinsic immune activation through STING pathway. Such immunogel achieved an encouraging anti-tumor effect with an 80 % total survival rate for recurrent tumors and a 60 % survival rate for metastatic tumors. Considering that this in situ immunogel possesses simple formulation and displays superior anti-tumor effect, this research provided a promising strategy for postoperative cancer therapy. Graphical abstract After surgery, a suppressed immune system increases the risk of tumor recurrence and metastasis. The novel immunogel in our study, a polymer hydrogel with pyroptosis inducers and adjuvants, works synergistically to enhance anti-tumor immunity and achieve survival rates of 80 % for recurrence and 60 % for metastasis. Download: Download high-res image (411KB) Download: Download full-size image

Sodium Alginate Hydrogel-Mediated Cancer Immunotherapy for Postoperative In Situ Recurrence and Metastasis

Efficient Synergistic Immunotherapy for Inhibiting Tumor Postoperative Recurrence and Metastasis via Calcium Alginate Hydrogel Nanosystem

Long-Acting Nanohybrid Hydrogel Induces Persistent Immunogenic Chemotherapy for Suppressing Postoperative Tumor Recurrence and Metastasis.

Co-localized Delivery of Nanomedicine and Nanovaccine Augments the Postoperative Cancer Immunotherapy by Amplifying T-cell Responses.

Engineered In-Situ-forming Biomimetic Hydrogel with Self-Regulated Immunostimulatory Capacity Promotes Postoperative Tumor Treatment

An Ultrasound‐Responsive and In Situ Gelling Hydrogel Nanocomposite for Boosting Anti PD‐L1 Immunotherapy via Remodeling Aberrant ECM of Post‐Surgical Residual Cancer

Immune Checkpoint-Regulatable Hydrogel-Immobilized Nanotherapeutics for Post-Surgical Treatment of Osteosarcoma

Gold nanorods-mediated efficient synergistic immunotherapy for detection and inhibition of postoperative tumor recurrence

Polymeric immunogel prevents tumor recurrence and metastasis by dual activation of innate and adaptive immunity

Ultrasensitive Optical Detection and Elimination of Residual Microtumors with a Postoperative Implantable Hydrogel Sensor for Preventing Cancer Recurrence.

In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment

In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma

Injectable Polydopamine Nanoparticle-Incorporated Hydrogels for Antiangiogenesis and Stimulating Tumoricidal Immunity to Inhibit Metastasis and Recurrence Postresection

Nitric Oxide Polymersome-Immobilized Hydrogels for Prevention of Post-Surgical Tumor Recurrence and Metastasis

Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis.

Enrichment and sensing tumor cells by embedded immunomodulatory DNA hydrogel to inhibit postoperative tumor recurrence

Overcoming neutrophil-induced immunosuppression in postoperative cancer therapy: Combined sialic acid-modified liposomes with scaffold-based vaccines

Immunogenic Hydrogel Toolkit Disturbing Residual Tumor "seeds" and Pre-Metastatic "soil" for Inhibition of Postoperative Tumor Recurrence and Metastasis.

Immunotherapeutic Hydrogel with Photothermal Induced Immunogenic Cell Death and STING Activation for Post‐Surgical Treatment

Immunotherapeutic hydrogel for co-delivery of STAT3 siRNA liposomes and lidocaine hydrochloride for postoperative comprehensive management of NSCLC in a single application

Hydrogel-mediated Tumor T Cell Infiltration and Immune Evasion to Reinforce Cancer Immunotherapy.